Baird Maintains Neutral on Biomarin Pharmaceutical, Lowers Price Target to $65
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Joel Beatty has maintained a Neutral rating on Biomarin Pharmaceutical (NASDAQ:BMRN) but has lowered the price target from $72 to $65.
October 30, 2024 | 11:28 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Baird analyst Joel Beatty has maintained a Neutral rating on Biomarin Pharmaceutical but has lowered the price target from $72 to $65.
The lowering of the price target from $72 to $65 by Baird suggests a less optimistic outlook on Biomarin's stock performance. This could lead to a negative short-term impact on the stock price as investors may adjust their expectations accordingly.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100